Crossmark

Comment on “Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study”

Crossref DOI link: https://doi.org/10.1016/j.aohep.2025.102127

Published Print: 2025-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Chen, Qing

Meng, Meng

Yuan, Chunhui
License Information

Text and Data Mining valid from 2025-07-01

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-09-23
More Information

This article is maintained by: Elsevier

Article Title: Comment on “Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study”

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2025.102127

Content Type: simple-article

Copyright: © 2025 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below